173 related articles for article (PubMed ID: 16870790)
1. AG205, a novel agent directed against FabK of Streptococcus pneumoniae.
Takahata S; Iida M; Osaki Y; Saito J; Kitagawa H; Ozawa T; Yoshida T; Hoshiko S
Antimicrob Agents Chemother; 2006 Aug; 50(8):2869-71. PubMed ID: 16870790
[TBL] [Abstract][Full Text] [Related]
2. Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK.
Ozawa T; Kitagawa H; Yamamoto Y; Takahata S; Iida M; Osaki Y; Yamada K
Bioorg Med Chem; 2007 Dec; 15(23):7325-36. PubMed ID: 17892940
[TBL] [Abstract][Full Text] [Related]
3. Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.
Kitagawa H; Ozawa T; Takahata S; Iida M; Saito J; Yamada M
J Med Chem; 2007 Sep; 50(19):4710-20. PubMed ID: 17713898
[TBL] [Abstract][Full Text] [Related]
4. Phenylimidazole derivatives as new inhibitors of bacterial enoyl-ACP reductase FabK.
Kitagawa H; Ozawa T; Takahata S; Iida M
Bioorg Med Chem Lett; 2007 Sep; 17(17):4982-6. PubMed ID: 17600706
[TBL] [Abstract][Full Text] [Related]
5. Atromentin and leucomelone, the first inhibitors specific to enoyl-ACP reductase (FabK) of Streptococcus pneumoniae.
Zheng CJ; Sohn MJ; Kim WG
J Antibiot (Tokyo); 2006 Dec; 59(12):808-12. PubMed ID: 17323650
[TBL] [Abstract][Full Text] [Related]
6. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
Seefeld MA; Miller WH; Newlander KA; Burgess WJ; DeWolf WE; Elkins PA; Head MS; Jakas DR; Janson CA; Keller PM; Manley PJ; Moore TD; Payne DJ; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Uzinskas IN; Wallis NG; Huffman WF
J Med Chem; 2003 Apr; 46(9):1627-35. PubMed ID: 12699381
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel and potent class of FabI-directed antibacterial agents.
Payne DJ; Miller WH; Berry V; Brosky J; Burgess WJ; Chen E; DeWolf WE; Fosberry AP; Greenwood R; Head MS; Heerding DA; Janson CA; Jaworski DD; Keller PM; Manley PJ; Moore TD; Newlander KA; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Salyers KL; Seefeld MA; Smyth MG; Takata DT; Uzinskas IN; Vaidya K; Wallis NG; Winram SB; Yuan CC; Huffman WF
Antimicrob Agents Chemother; 2002 Oct; 46(10):3118-24. PubMed ID: 12234833
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK).
Marrakchi H; Dewolf WE; Quinn C; West J; Polizzi BJ; So CY; Holmes DJ; Reed SL; Heath RJ; Payne DJ; Rock CO; Wallis NG
Biochem J; 2003 Mar; 370(Pt 3):1055-62. PubMed ID: 12487627
[TBL] [Abstract][Full Text] [Related]
9. Panosialins, inhibitors of enoyl-ACP reductase from Streptomyces sp. AN1761.
Kwon YJ; Sohn MJ; Oh T; Cho SN; Kim CJ; Kim WG
J Microbiol Biotechnol; 2013 Feb; 23(2):184-8. PubMed ID: 23412060
[TBL] [Abstract][Full Text] [Related]
10. Vinaxanthone, a new FabI inhibitor from Penicillium sp.
Zheng CJ; Sohn MJ; Kim WG
J Antimicrob Chemother; 2009 May; 63(5):949-53. PubMed ID: 19282328
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae reveals the binding mode of an inhibitor.
Saito J; Yamada M; Watanabe T; Iida M; Kitagawa H; Takahata S; Ozawa T; Takeuchi Y; Ohsawa F
Protein Sci; 2008 Apr; 17(4):691-9. PubMed ID: 18305197
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.
Takahata S; Iida M; Yoshida T; Kumura K; Kitagawa H; Hoshiko S
J Antibiot (Tokyo); 2007 Feb; 60(2):123-8. PubMed ID: 17420562
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.
Kim YG; Seo JH; Kwak JH; Shin KJ
Bioorg Med Chem Lett; 2015 Oct; 25(20):4481-6. PubMed ID: 26343826
[TBL] [Abstract][Full Text] [Related]
14. Verrulactone C with an unprecedented dispiro skeleton, a new inhibitor of Staphylococcus aureus enoyl-ACP reductase, from Penicillium verruculosum F375.
Kim N; Sohn MJ; Koshino H; Kim EH; Kim WG
Bioorg Med Chem Lett; 2014 Jan; 24(1):83-6. PubMed ID: 24332629
[TBL] [Abstract][Full Text] [Related]
15. CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.
Park HS; Yoon YM; Jung SJ; Yun IN; Kim CM; Kim JM; Kwak JH
Int J Antimicrob Agents; 2007 Nov; 30(5):446-51. PubMed ID: 17723291
[TBL] [Abstract][Full Text] [Related]
16. Aquastatin A, a new inhibitor of enoyl-acyl carrier protein reductase from Sporothrix sp. FN611.
Kwon YJ; Fang Y; Xu GH; Kim WG
Biol Pharm Bull; 2009 Dec; 32(12):2061-4. PubMed ID: 19952429
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel thiazole derivatives as potent FabH inhibitors.
Lv PC; Wang KR; Yang Y; Mao WJ; Chen J; Xiong J; Zhu HL
Bioorg Med Chem Lett; 2009 Dec; 19(23):6750-4. PubMed ID: 19836235
[TBL] [Abstract][Full Text] [Related]
18. Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.
Zheng CJ; Sohn MJ; Lee S; Kim WG
PLoS One; 2013; 8(11):e78922. PubMed ID: 24312171
[TBL] [Abstract][Full Text] [Related]
19. Streptococcus pneumononiae gyrase ATPase: development and validation of an assay for inhibitor discovery and characterization.
Miller JR; Herberg JT; Tomilo M; McCroskey MC; Feilmeier BJ
Anal Biochem; 2007 Jun; 365(1):132-43. PubMed ID: 17395144
[TBL] [Abstract][Full Text] [Related]
20. Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers.
Yao J; Zhang Q; Min J; He J; Yu Z
Bioorg Med Chem Lett; 2010 Jan; 20(1):56-9. PubMed ID: 19959361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
